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doi:10.1016/j.ejvs.2010.10.007Abstract Objective: Management of anti-platelet therapy during carotid artery stenting
(CAS) is mainly based on indirect evidence from coronary stenting experience. There is
common agreement on the use of thienopyridine (mainly second-generation) during CAS, but
some patients are unsuitable for clopidogrel treatment and data on the benefit of its use in
large CAS populations are lacking. The aim of this study was to investigate whether clopidogrel
was associated with reduced perioperative morbidity in patients undergoing CAS.
Methods: Consecutive patients undergoing CAS for primary carotid stenosis from 2004 to 2009
were reviewed. The independent association of clopidogrel and perioperative morbidity was
assessed using multivariable analysis.
Results: A total of 1083 patients were treated (29% females, mean age 71.6 years); 825 (76%)
patients were given clopidogrel starting before treatment. Clopidogrel use was associated with
a non-significant reduction of perioperative stroke/death (4.3% vs. 2.4%; p Z 0.13) and
disabling stroke (1.2% vs. 1.0%; p Z 1) rates. The non-significant stroke/death difference
was similar in symptomatic (5.8% vs. 4.0%, p Z 0.37) and asymptomatic (3.7% vs. 1.9%;
pZ 0.17) patients. After adjusting for demographics, co-morbidities and other therapies with
multivariable analysis, clopidogrel use failed to show any significant independent association
in decreasing operative risks. The only independent protective factor was use of statins
(p Z 0.010). The additional use of dual anti-platelet therapy did not add any advantage to
the use of clopidogrel alone.
Conclusions: The suggested benefit of clopidogrel in decreasing the incidence of complications
in patients undergoing CAS may be overestimated due to the overlapping effect of other more, Vascular and Endovascular Unit, Hospital S. M. Misericordia, University of Perugia, 06134 Perugia,
075 5786435.
il.com, pderango@unipg.it (P. De Rango).
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Carotid Artery Stenting and Clopidogrel 215relevant factors (e.g., pleiotropy and plaque stabilisation from statins). More data and level I
evidence are needed to understand which is the best medical management of CAS that will
help improve outcomes of the procedure.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Thienopyridines are now one of the most widely used drugs
for the treatment and prevention of cardiovascular disease,
and their use has been increasingly implemented among
individuals with acute coronary syndromes, who are at high-
risk of thrombosis and ischaemic complications.1e4 Today,
there is little debate that clopidogrel therapy (the most
largely studied thienopyridine) prevents complications and
mortality in patients with coronary heart syndromes.
Nevertheless, insight is significantly lacking regarding the
effects of clopidogrel treatment on periprocedural or long-
term outcome in patients undergoing carotid artery stenting
(CAS). Although anti-platelet therapy is unquestionably
beneficial in CAS, the routine use of clopidogrel in this setting
has been mainly extracted from coronary artery litera-
ture.5,6 In the context of current randomised controlled
trials (RCTs), patients with cerebrovascular disease or
multiple cardiovascular risk factors without a primary event
do not appear to obtain a net benefit from dual aspirin and
clopidogrel therapy.1,7e11 Clopidogrel efficacy in decreasing
the risk of acute/sub-acute carotid stent thrombosis, a rare
but potentially fatal complication of CAS, is also mainly
derived from coronary data.12 Furthermore, there is still
large uncertainty in the use of clopidogrel with respect to
appropriate regimen, starting time, length of therapy,
dosing, combination strategy with other anti-platelet drugs,
risk of bleeding and potential for variable platelet
response.1,2,10,11 In the absence of convincing data in carotid
procedures, the routine use of clopidogrel during and after
CAS might be an object of debate.
To provide additional information in this field, we
reviewed our experience with CAS to investigate whether
second-generation thienopyridine use was associated with
reduced perioperative mortality and morbidity.
Methods
Patients with high-grade (>70% as assessed with duplex
ultrasound and confirmed at angiography) primary carotid
stenosis treated by CAS at a single vascular surgery centre
after the training phase were analysed. For the purpose of
the study, patients who received CAS for recurrent carotid
stenosis and CAS performed within the training phase
(2001e2003) were excluded. Patients were analysed
according to the treatment they actually received (on-
treatment analysis). Patients scheduled for CAS and even-
tually converted to surgery (carotid endarterectomy, CEA)
because of CAS failure were not included.
Medical records were entered in a prospectively
compiled database andwere reviewed for the present study.
Study variable
The exposure variable for this study was medication with
clopidogrel at the time of the CAS procedure. Patients
scheduled for CAS usually received anti-platelet therapyconsisting of a dual-drug regimen: acetylsalicylic acid (ASA)
(125e325 mg once daily) and clopidogrel (75 mg/die) for at
least 30 days after a 300 mg loading dose administered
6e12 h before CAS. A loading dose was not used when
clopidogrel therapy was started more than 3 days before
CAS. A number of patients could not follow the used
regimen and were not started on clopidogrel as:
 they demonstrated intolerance to clopidogrel;
 were already on anticoagulation;
 were already on other thienopyridine drug (usually
first-generation ticlopidine);
 there was lack of preprocedural window time (emer-
gency treatment).
All these patients were considered clopidogrel non-
takers and were counted together as a single variable for
the purpose of the analysis. Patients under ticlopidine
(250 mg twice daily) or receiving anticoagulation for co-
existing medical co-morbidities continued to receive their
baseline therapy at their usual dose.
Patients who were not compliant with dual anti-platelet
therapy (e.g., previous reaction to one or other anti-
platelet drug, recent history of bleeding and gastric intol-
erance) were left on a single-drug regimen (including or not
clopidogrel, depending on the reasons stated above).
Written consent was obtained from all patients before
revascularisation.
Patient evaluation
Features and time of preoperative symptoms were eval-
uated by external neurological audit. Patients were
defined symptomatic when ipsilateral hemispheric or
retinal symptoms occurred within 6 months from the
procedure.
The degree and characteristics of carotid stenosis were
assessed with duplex ultrasound. ‘Complex carotid plaque’
was judged by ultrasound when a lack of uniform pattern
and prevalence of soft appearance was evident. Contrast-
enhanced computed tomography (CT) was performed
selectively, in the case of uncertainty at ultrasound
examination. Cerebral CT scan was used in symptomatic
patients to assess the extent of recent lesions, if any.
CAS procedure
CAS was carried out following a standardised protocol in an
endovascular room equipped with a high-quality fixed
imaging system (Axiom Artis FA, Siemens).
All procedures were performed with cerebral protection
devices (CPDs) and different stent models (open cell, close
cell or hybrid configuration; tapered or straight). The
choice of specific material depended on vessel anatomy
and lesion characteristics.
Stent size and length were chosen according to preop-
erative measurements of the target vessel by Doppler
216 P. De Rango et al.ultrasound or CT examination. Closure devices for access
control have been used since 2006.
Outcome measures and definitions
The pre-specified primary outcome was the combined risk
of any stroke or death within 30 days or during hospital-
isation (perioperative). Secondary outcomes were any
perioperative stroke, disabling stroke, transient ischaemic
attack (TIA), myocardial infarction (MI), local complications
(haematoma and pseudo-aneurysm) and stent thrombosis/
occlusion.
In the presence or suspicion of new neurological or
cardiac events, a team of neurologists and cardiologists was
routinely consulted and documented the presence, the
type and the severity (National Institute of Health (NIH)
Stroke Scale) of the event. Neurological condition was
constantly monitored in all the patients. New-onset post-
operative neurological deficits lasting less than 24 h in the
absence of new focal cerebral lesions were defined as TIAs.
Stroke was defined as any new hemispheric or retinal
neurological event persisting >24 h and classified as fatal,
disabling (modified Rankin Score 3) or non-disabling
(modified Rankin Score <3).
Statistical analysis
Tests of statistical significance comparing clopidogrel takers
and non-takers were conducted using c2 and Fisher’s exact
test for categorical variables and analysis of variance
(ANOVA) and t-test for continuous variables. Unadjusted and
adjusted odds ratios (ORs) with correspondent 95% confi-
dence intervals (CIs) were used to compare outcomes
between clopidogrel takers and non-takers.
Patient characteristics, including demographics, plaque,
technical issues, co-morbidities andmedication thatmight be
associated with increased cerebrovascular risk complication
during CAS were analysed. A list of patients’ assessed vari-
ables is reported in Table 1.
The association between variables and the combined
periprocedural (within 30 days) risk of any stroke or death
was first assessed by the univariate logistic method.Table 1 Characteristics in clopidogrel and non-clopidogrel grou
Total n 1083 NO clo
Age (mean), years 71.6 71.9 
Age 75 years 439 109 (42
Female 314 72 (27
Diabetes 333 87 (33
Hypertension 905 217 (84
CAD 397 111(43
Hyperlipidemia 671 156 (60
Statins 465 94 (36
PAD 147 42 (16
Symptomatic 268 69 (26
Contralateral Occlusion 82 22 (8.
Complex Plaque 338 83 (32
Open cell stent 314 66 (25
Debrisa 423 107 (41
CAD: Coronary artery disease; PAD: Peripheral artery disease.
a Macroscopic debris during procedure.Two different multivariate logistic regression models
were then used to adjust the crude OR and assess the
independent association between use of clopidogrel and
primary end point (perioperative stroke/death): the first
using all patient characteristics, and the second using only
significant patient characteristics identified by backward
elimination, univariate analysis or which were imbalanced
between the clopidogrel and not-clopidogrel takers.
Given the virtually identical findings from these two
modelling approaches, and the small number of outcome
events that had occurred, only results from the second are
presented.
The model fit was assessed by using the Hosmere
Lemeshow goodness-of-fit method.
Subgroup analyses by preoperative symptoms gender
and age (less or more than 75 years) were performed.
For all tests, a probability value of p < 0.05 was
considered statistically significant. Statistical Package for
Social Sciences (SPSS)/PC version 13.00 Win package (SPSS
for Windows Chicago, IL, USA 2003) was used for all data
analyses.
Results
A total of 1083 CAS procedures in 1007 patients were per-
formed for severe primary carotid stenosis between
January 2004 and March 2009. There were 314 (29%)
females and 769 (71%) males with a mean age of
71.53  7.47 (range 48e92 years). As many as 268 (24.8%)
CAS procedures were performed in patients with docu-
mented neurological symptoms in the last 6 months before
the procedure, whereas the remaining 815 (75.2%) were in
patients without clinical symptoms. Co-morbidities,
demographics and baseline medications are shown in
Table 1.
At the time of operation, 825 (76%) patients were taking
clopidogrel according to the standardised protocol, while in
258 (24%), clopidogrel could not be used. In 754 (70%) CAS
procedures, clopidogrel was employed within dual anti-
platelet regimen (associated with ASA). Any type of dualps.
pidogrel n 258 Clopidogrel n 825 P value
7.0 71.4  7.5 0.26
.2%) 330 (40%) 0.56
.9%) 242 (29.3%) 0.69
.7%) 246 (29.8%) 0.24
.1%) 688 (83.4%) 0.84
.0%) 286 (34.6%) 0.018
.4%) 515 (62.4%) 0.55
.4%) 371 (44.9%) 0.017
.2%) 105 (12.7%) 0.15
.7%) 199 (24.1%) 0.4
5%) 60 (7.3%) 0.5
.1%) 255 (30.9%) 0.75
.6%) 248 (30%) 0.20
.5%) 316 (38.3%) 0.38
Table 2 Perioperative outcome.
NO Clopidogrel
n 258
Clopidogrel
n 825
Absolute
difference
OR CI 95% P value
Stroke/Death 11 (4.3%) 20 (2.4%) 1.9 0.56 0.26e1.18 0.13
Stroke 11 (4.3%) 20 (2.4%) 1.9 0.56 0.26e1.18 0.13
Death e e
Disabling stroke 3 (1.2%) 9 (1.1%) 0.1 0.93 0.25e3.49 1.0
TIA 10 (3.9%) 29 (3.5%) 0.4 0.87 0.42e1.82 0.7
MI 1 (0.4%) 2 (0.2%) 0.2 0.62 0.06e6.92 0.6
MACE 13 (5.0%) 23 (2.8%) 2.2 0.54 0.27e1.08 0.1
Hematoma/pseudo-aneurysm 6 (2.3%) 9 (1.1%) 1.2 0.46 0.16e1.31 0.2
Stent removal/acute thrombosis 3 (1.2%) 1 (0.1%) 1.1 0.10 0.01e0.99 0.04
TIA: Transient Ischemic Attack; MI: Myocardial infarction; MACE: Major Adverse Clinical Events (Stroke, death and MI).
Carotid Artery Stenting and Clopidogrel 217anti-platelet (with or without clopidogrel) therapy was
employed in 814 CAS (75.2%) procedures. There were 42
(3.8%) patients under anticoagulation, 145 (13.4%) under
ticlopidine and 863 (80%) under ASA, either alone or in
combination anti-platelet strategy.
The use of clopidogrel increased slightly over the years:
percentages of clopidogrel takers were 72% (n Z 117) in
2004, 73.5% (n Z 103) in 2005, 77.8% (n Z 232) in 2006,
74.6% (n Z 173) in 2007 and 80% (n Z 200) in 2008/2009.
Patients not taking clopidogrel had coronary artery disease
more frequently (43.0% vs. 34.6%; p Z 0.018), while the
concurrent preoperative use of statin was more likely (44.9%
vs. 36.4%;pZ 0.017) in the clopidogrel group (Table 1). There
were no imbalances between clopidogrel and non-clopidogrel
users with regard to age (p Z 0.26), gender (p Z 0.69) and
symptomatic disease (pZ 0.4).
Perioperative morbidity
There were 31 perioperative strokes and no perioperative
death for a combined perioperative stroke or death rate ofTable 3 Perioperative stroke or death rate. Univariate analysis
Variables CAS
with variable
Events in
CAS with variable
Age (mean), years 71.6a 73.6a
Age 75 years 439 3.4%
Females 314 2.2%
Diabetes 333 2.4%
Hypertension 905 2.8%
CAD 397 2.5%
PAD 147 2.7%
Contralateral occlusion 82 6.1%
Symptomatic 268 4.5%
Complex plaque 338 3.5%
Debrisb 423 3.8%
Open cell stent 314 2.5%
Clopidogrel 258 2.4%
Clopidogrel dual 754 2.4%
Dual anti-platelet
(any type)
814 2.6%
Statin 465 1.3%
CAD: Coronary artery disease; PAD: Peripheral artery disease.
a Mean age.
b Macroscopic debris during procedure.2.8%. Twelve strokes were disabling (1.1%). MI occurred in
three (0.3%), TIA in 39 (3.6%) and any major adverse clinical
event (MACE: stroke or death or MI) in 36 (3.3%) cases.
The distribution of perioperative complications was not
significantly different between clopidogrel and non-clopi-
dogrel takers. The details of perioperative complications
are shown in Table 2.
Univariate analysis failed to show significant association
between the use of clopidogrel and decreased perioperative
rates of stroke/death: 4.3% vs. 2.4%, in non-clopidogrel
versus clopidogrel takers (OR 0.56, 95% CI 0.26e1.18;
p Z 0.13). Only the preoperative use of statin was
(pZ 0.009) significantly associated with decreased primary
outcome (perioperative death/stroke rate) at univariate
analysis (Table 3).
There were no significant associations between the use
of clopidogrel and other complications, including disabling
stroke, MACE, MI and haematoma/pseudo-aneurysm (Table
2). Similar results were found when only the subgroup of
754 clopidogrel takers within the dual anti-platelet regimen
(censoring mono-drug takers) was analysed: stroke and.
Events in
CAS without variable
OR 95% CI P value
71.4a 1.3 4.84e0.49 0.11
2.5% 0.7 0.35e1.47 0.46
3.1% 0.7 0.30e1.66 0.54
3.1% 0.8 0.34e1.76 0.69
3.4% 0.8 0.33e2.00 0.62
3.1% 0.8 0.38e1.75 0.71
2.9% 0.9 0.32e2.70 1.0
2.6% 2.4 0.91e6.51 0.08
2.3% 1.9 0.94e4.10 0.09
2.6% 1.4 0.67e2.91 0.43
2.3% 1.7 0.83e3.45 0.19
2.9% 0.9 0.39e2.00 0.84
4.3% 0.6 0.26e1.18 0.13
3.7% 0.6 0.29e1.37 0.29
3.3% 0.7 0.33e1.74 0.50
4.0% 0.31 0.12e0.76 0.009
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218 P. De Rango et al.death 2.4% (n Z 18); disabling strokes 1.1% (n Z 8); TIA
3.6% (n Z 27); MI 0.3% (n Z 2); MACE 2.7% (n Z 20); and
haematoma 1.1% (n Z 8).
Multivariate analysis, adjusting for confounders with
backward selection, confirmed the lack of association
between perioperative stroke/death rate and use of clo-
pidogrel (OR 0.6; 95% CI: 0.28e1.3; p Z 0.20). Lack of
effect was also detected for clopidogrel used exclusively as
dual anti-platelet therapy. Statin use remained indepen-
dently associated with over threefold reduction of the
hazard of perioperative stroke/death: OR 0.31, 95% CI
0.13e0.76; p Z 0.010 (HosmereLemeshow goodness-of-fit
analysis; p Z 0.26).
After completion of the procedure, four stents were
acutely removed (Table 4). Only one of these patients was
under clopidogrel at the time of the primary procedure.
Two were on oral anticoagulant for atrial fibrillation and
the third was on ASA alone because of treatment in
emergency for an acute deficit. In this patient, the stent
thrombosis occurred 2 h after CAS, and was associated
with a transient ocular deficit that totally recovered in
few minutes. In a female patient, repeated TIAs devel-
oped after stent deployment for plaque protrusion
through the stent struts. Stent removal occurred the day
after. Two other male patients developed stent throm-
boses immediately after procedure for asymptomatic
carotid stenosis. In one, this was associated with occur-
rence of two transient brachialecrural arm deficits (few
minutes) after an uneventful procedure. The last patient
with stent removal, treated for preocclusive carotid
stenosis, had developed alteration of consciousness after
stent ballooning, and completion angiography showed
complete occlusion of the stent. Due to the preocclusive
lesion, it was indicated to proceed immediately with
carotid surgery and stent removal. In all these cases,
duplex ultrasound was performed immediately upon the
occurrence of deficits to diagnose stent patency. All the
four patients were uneventfully converted to CEA. Details
are shown in Table 4.
Subgroup analyses
Subgroup analyses by symptoms, gender and age were
performed. Perioperative stroke/death risk was not signif-
icantly lower in asymptomatic (15/815; 1.8%) versus
symptomatic (12/268; 4.47%; pZ 0.08), in females (7/314;
2.2%) versus males (24/769; 3.1%; p Z 0.54) and in <75
years old (16/644; 2.5%) versus 75 years old (15/439;
3.4%; p Z 0.45) patients.
The lack of association between the use of clopidogrel
and stroke/death rate by symptoms and gender was
confirmed in both univariate (Table 5, Fig. 1) and multi-
variate analyses (Fig. 2). The non-significant stroke/death
difference between clopidogrel takers and not takers was
similar in symptomatic (4.0% vs. 5.8%; p Z 0.37) and
asymptomatic (1.9% vs. 3.7%; p Z 0.17) patients, in
females (1.6% vs. 4.2%; p Z 0.20) and in males (2.7% vs.
4.3%; pZ 0.33). The addition of dual therapy to clopidogrel
did not provide adjunctive benefit (analyses of the
subgroup of 754 clopidogrel takers as dual therapy showed
similar findings).
There was no association between use of clopidogrel
and perioperative stroke/death in the younger (<75 years)
Table 5 Perioperative stroke and death rate in subgroup analysis. Univariate analysis.
Tot
(n Z 1083)
No Clopidogrel
(n Z 258)
Clopidogrel
(n Z 825)
Absolute
difference
OR 95% CI P value
Gender N N
Females 314 3/72 (4.2%) 4/242 (1.6%) 2.6 0.4 0.08e1.76 0.20
Males 769 8/186 (4.3%) 16/583 (2.7%) 1.6 0.6 0.26e1.4 0.33
Age
<75 years 644 4/149 (2.7%) 12/495 (2.4%) 0.3 0.9 0.28e2.84 0.77
75 years 439 7/109 (6.4%) 8/330 (2.4%) 4.0 0.3 0.12e1.02 0.06
Indication
Symptomatic 268 4/69 (5.8%) 8/199 (4.0%) 1.8 0.7 0.19e2.33 0.37
Asymptomatic 815 7/189 (3.7%) 12/626 (1.9%) 1.8 0.5 0.19e1.31 0.17
Carotid Artery Stenting and Clopidogrel 219patients’ subgroup: 2.4% versus 2.7% (in clopidogrel vs.
non-clopidogrel takers; p Z 0.77). For the subgroup of
older (>75 years) patients, there was a trend towards
a protective effect of clopidogrel use on perioperative
stroke/death rate: 2.4% versus 6.4% in clopidogrel versus
non-clopidogrel takers, OR 0.36; 95% CI 0.12e1.023;
pZ 0.06. This trend was confirmed by multivariate analysis
where the use of clopidogrel was selected by backward
elimination in the last step of the analysis (p Z 0.07, OR
0.38, 95% CI 0.13e1.0) as well as contralateral occlusion
(p Z 0.018, OR Z 4.3, 95% CI 1.29e14.6), the only signif-
icant predictor.Figure 1 Subgroup analyses by gender, preoperative symp-
toms and age in clopidogrel takers according to univariate
analysis. Risk of perioperative stroke/death is shown as OR
(square box) and Confidence intervals (horizontal line
boundaries).Discussion
Among patients undergoing CAS, use of clopidogrel in the
periprocedural period (30 days) was associated with a non-
significantly lower periprocedural mortality and stroke rate
with respect to no use of clopidogrel: 2.4% versus 4.3%;
p Z 0.13. The decreased perioperative stroke/death risk
was not robust when adjusted for the relationship between
prognostic variables and outcome, and for the confounding
effect by concurrent treatment with a statin. This finding
extended to patients undertaking another anti-platelet
drug associated with clopidogrel and occurred in both
asymptomatic and symptomatic patients undergoing CAS. In
addition, there was no evidence of better cardiac outcome
associated with clopidogrel. Even though the non-clopi-
dogrel group included more patients with coronary disease
and patients treated acutely (without window time for
clopidogrel loading dose), outcomes were not significantly
different from the clopidogrel group.
The suggested lower procedural risk in clopidogrel takers
ismainly based onfindings from coronary literature.1,5,6 Only
one small RCT has directly analysed outcomes after carotid
stenting in clopidogrel versus non-clopidogrel takers, and the
results of this study in favour of clopidogrel may not be
generalised.13 The routine use of clopidogrel during CAS
seems to be not supported by adequate evidence.13,14
The occurrence of rapid thrombus formation immedi-
ately after arterial injury and stenting and potential
embolisation of the thrombus to distal sites provides the
rationale for early use of clopidogrel therapy during
stenting. It has been suggested that intimal injury of theartery during percutaneous interventions can release pro-
coagulant tissue factors and expose collagen and other
platelet-adhesive proteins in the subendothelium, thereby
triggering the formation of a platelet-rich thrombus that
seals the site of injury. However, almost all our information
on arterial injury and stent thrombosis is from coronary
circulation,12,15 while there are inconsistent data to
support the efficacy of clopidrogrel in preventing acute/
sub-acute carotid stent thrombosis, a rare but potentially
catastrophic complication reported after CAS.16,17
The extent of platelet deposition and thrombus forma-
tion on the arterial wall after injury is dependent on the
degree of vessel-wall injury and local shear forces,
accounting for a number of differences between coronary
and carotid vessels.12,15 During carotid stenting, operator
experience has more significance than the formation of
a new platelet-rich thrombus on the injured wall in trig-
gering cerebral ischaemic complications. Furthermore, due
to the larger size of the carotid vessel and the lower shear
stress, thrombosis risk is less likely with respect to coronary
arteries. In our experience, the risk of stent removal for
early thrombosis was more frequent in the clopidogrel non-
takers group. However, data were provided from only four
Figure 2 Association between clopidogrel use and rates of
perioperative stroke/death in subgroup analyses by gender,
preoperative symptoms and age according to multivariate
analysis. Risk of perioperative stroke/death is shown as OR
(square box) and Confidence intervals (horizontal line
boundaries).
220 P. De Rango et al.CAS procedures, and it was more likely that technical errors
have affected the early thromboses and the protrusion of
plaque through the stent struts.
In our study, although the majority of patients were
taking clopidogrel, the benefit could not be proven with
respect to the minority of patients not taking clopidogrel.
Our results would not suggest that clopidogrel is not
effective in patients undergoing CAS but more likely that
the benefit of clopidogrel in endovascular carotid proce-
dures might be overestimated, based on inaccurate
assumptions from coronary procedures. However, we
cannot exclude that lack of maximal efficacy of clopi-
dogrel in our study was due to the small numbers or
patient resistance to clopidogrel, either genetic or
related to concurrent assumption of receptorecompetitor
drug, as we did not investigate these issues. Neverthe-
less, we should hypothesise that the resistance against
the drug was considerable to counterbalance the overall
beneficial effect, while literature data on the clinical
relevance of clopidogrel resistance are conflicting and not
consistent.18
Our patients on clopidogrel undergoing CAS were more
likely to have a statin as a concurrent medication (this
likely reflects factors such as individual physician practice
or ability to pay for medication or compliance with drugs,
which were not captured in our study). When we analysed
the independent effect of statin and clopidogrel on primary
outcome (perioperative stroke/death), an association with
decreased outcome was confirmed only for statin and not
for clopidogrel use. We could infer that the true benefit in
outcome might be due to an overlapping ‘fog’ effect of
statins hidden by clopidogrel. Statins exhibit many prop-
erties that may be protective at the time of surgery and
endovascular procedures, including anti-thrombotic
actions, the ability to stabilise atherosclerotic plaque and
neuroprotective actions such as attenuating inflammatory
response and antioxidant activity.19 Some of these effects
could be shared by statins and clopidogrel, but statins
have an additional pleiotropic anti-inflammatory role inplaque stabilisation likely resulting in a stronger benefit
in decreasing ischaemic complications. There is increasing
evidence that the use of statin is today a mainstay in the
management of vascular patients.19 The findings of our
study support this hypothesis.
Use of clopidogrel during CAS might be more beneficial
in some subgroups of patients, such as the elderly. In our
study, patients 75 years old without clopidogrel showed
a fourfold perioperative stroke risk than clopidogrel takers:
6.4% versus 2.4%; p Z 0.06. Although the drug might be
helpful in decreasing the procedural risk in older patients,
it is also known that advanced age is a risk factor for CAS,
and most old patients should be excluded from the proce-
dure.20 More data and prospective analyses are needed to
confirm this hypothesis and to investigate the role of clo-
pidogrel in CAS subgroups.
Limitations of this study include, at first, the retro-
spective analysis and the lack of randomisation. Despite the
statistical methods (multivariable analyses) employed, we
could not exclude selection biases. Second, the number of
clopidogrel non-takers was unbalanced (n Z 258) when
compared with clopidogrel takers (n Z 825). There is the
possibility that a true effect of clopidogrel on outcome
might be hidden by the low frequency of outcomes
observed and the small numbers at risk. Third, the resis-
tance to drug, as well as the concurrent assumption of
proton pump inhibitors invalidating the effect of clopidog-
rel, was not tested; however, literature data on the clinical
relevance of clopidogrel resistance are conflicting. Finally,
we analysed exclusively early outcome, as, in most of our
patients, clopidogrel was used for 30 days after procedure
and then discontinued.
Conclusions
Use of anti-platelet is a mainstay in the management of
patients undergoing carotid revascularisation. Although
benefit from clopidogrel in decreasing the complication of
stroke during CAS is likely, the true effect might be over-
estimated as the efficacy of clopidogrel during carotid
endovascular procedure is supported by insufficient and
indirect evidence. Complications of CAS, more than of
coronary interventions, benefit from operator experience
and case selection. The overlapping adjunctive benefit of
other drugs (e.g., statin) should also be considered. More
accurate and in-depth knowledge is essential to provide
optimal medical management of patients undergoing CAS.
Future, prospective, randomised and large studies will be
helpful to clarify the extent of efficacy of new and old
thienopyiridines in decreasing adverse perioperative
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